Accession Number : ADA463435


Title :   Identification of Splice Variants as Molecular Markers in Parkinson's Disease


Descriptive Note : Annual rept. 1 Sep 2005-31 Aug 2006


Corporate Author : ROSALIND FRANKLIN UNIV OF MEDICINE AND SCIENCE CHICAGO IL


Personal Author(s) : Meredith, Gloria E


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a463435.pdf


Report Date : Sep 2006


Pagination or Media Count : 35


Abstract : Alternative splicing is responsible for producing several products from a single transcript and can cause pathogenic changes in RNA in neurodegenerative disease. This proposal tests the hypothesis that regulation of normal splicing is disrupted in Parkinson's disease (PD). Scope: Experiments are designed to determine splicing products in the brain and blood of experimental MPTP models of PD and the blood of newly diagnosed PD patients, who are not yet on dopamine therapy. The overall goal is to use splice variants as biomarkers to identify individuals at risk for PD. To date, we have identified and quantified alternatively spliced transcripts for several candidate genes in MPTP models of PD. We have also obtained RB permission to study splicing factors in the blood of newly diagnosed PD patients. Major Findings: Mice treated chronically with MPTP show a shift in the ratio of FosB, RGS9 and Ania6 splice variants in the striatum, 3 days post-treatment. The splicing ratios for AChE and Ania 6 also change in the blood following chronic treatment and, for Ania 6, the changed ratio persists up to 3 weeks after treatment. Progress in the first year includes 4 abstracts, a peer-reviewed publication and an article in preparation.


Descriptors :   *SPLICES , *PARKINSONS DISEASE , TEST AND EVALUATION , BRAIN , MOLECULES , DISEASES , VARIATIONS , IDENTIFICATION , THERAPY , TRACER STUDIES , NERVE CELLS , GENES , MARKERS , HYPOTHESES , DOPAMINE , BLOOD


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE